Syndax Pharmaceuticals Inc

SNDX

Explore Our Financial Data > Companies > Syndax Pharmaceuticals Inc
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
SNDX
CIK0001395937
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM, MA, 02451
Website syndax.com
Phone781-419-1400
CEOMichael A. Metzger
Employees110

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$172.35 million
Pre-Tax Income$-285.42 million
Net Income$-285.42 million
Net Income to Common$-285.42 million
EPS$-3.29
View All
Balance Sheet
Cash$134.93 million
Assets$529.71 million
Liabilities$465.08 million
Common Equity$64.63 million
Liabilities & Equity$529.71 million
View All
Cash Flow Statement
Net Income$-285.42 million
Cash From Operating Activities$-322.98 million
Cash From Investing Activities$290.04 million
Cash From Financing Activities$13.68 million
Change in Cash$-19.27 million
View All
Calculations
NOPAT$-191.16 million
EBITDA$-284.89 million
Price to EarningsN/A
Price to Book$33.07
ROE-161.82%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencemen

Article Link

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

Article Link

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.

Article Link

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.

Article Link

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

Article Link